company background image
REGN

Regeneron Pharmaceuticals NasdaqGS:REGN Stock Report

Last Price

US$688.87

Market Cap

US$73.6b

7D

-1.2%

1Y

20.7%

Updated

02 Oct, 2022

Data

Company Financials +
REGN fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends0/6

REGN Stock Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

Regeneron Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Regeneron Pharmaceuticals
Historical stock prices
Current Share PriceUS$688.87
52 Week HighUS$754.67
52 Week LowUS$538.01
Beta0.28
1 Month Change18.64%
3 Month Change15.70%
1 Year Change20.69%
3 Year Change143.48%
5 Year Change46.58%
Change since IPO3,160.92%

Recent News & Updates

Sep 29

Sanofi, Regeneron win FDA label expansion for Dupixent in chronic, skin condition

The FDA has approved Dupixent, developed by Regeneron (NASDAQ:REGN) and Sanofi (NASDAQ:SNY) (OTCPK:SNYNF) (GCVRX), for adults with prurigo nodularis, a chronic, inflammatory skin condition.  The subcutaneously administered treatment is already indicated in the U.S. for conditions including atopic dermatitis and asthma, and the prurigo nodularis is the second skin condition the drug is greenlighted in the U.S. The decision is based on data from two Phase 3 trials, PRIME and PRIME2, in which 60% and 58% of Dupixent-treated patients witnessed a clinically meaningful decline in itch at 24 weeks from the baseline compared to 18% and 20% for placebo, as the primary endpoint. “Dupixent has the potential to transform the standard-of-care for prurigo nodularis patients by alleviating the key hallmarks of the disease, such as reducing itch and achieving clearer skin,” remarked Naimish Patel, Head of Global Development, Immunology and Inflammation at Sanofi (SNY). During Q2 2022, Dupixent added €1.96B in sales for Sanofi (SNY) with ~43% YoY growth.

Shareholder Returns

REGNUS BiotechsUS Market
7D-1.2%0.4%-2.5%
1Y20.7%-25.6%-23.2%

Return vs Industry: REGN exceeded the US Biotechs industry which returned -25.6% over the past year.

Return vs Market: REGN exceeded the US Market which returned -23.2% over the past year.

Price Volatility

Is REGN's price volatile compared to industry and market?
REGN volatility
REGN Average Weekly Movement6.7%
Biotechs Industry Average Movement11.1%
Market Average Movement6.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: REGN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: REGN's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198810,715Leonard Schleiferhttps://www.regeneron.com

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.

Regeneron Pharmaceuticals, Inc. Fundamentals Summary

How do Regeneron Pharmaceuticals's earnings and revenue compare to its market cap?
REGN fundamental statistics
Market CapUS$73.65b
Earnings (TTM)US$5.69b
Revenue (TTM)US$14.23b

13.0x

P/E Ratio

5.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
REGN income statement (TTM)
RevenueUS$14.23b
Cost of RevenueUS$5.23b
Gross ProfitUS$9.00b
Other ExpensesUS$3.31b
EarningsUS$5.69b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)53.19
Gross Margin63.26%
Net Profit Margin39.97%
Debt/Equity Ratio9.6%

How did REGN perform over the long term?

See historical performance and comparison